NOTICE 1 페이지

NEWS & EVENT

Total 12 - 1 page

No	Subject	Date	Hit
12	신주발행공고	2026.03.12	1,078
익명 1,078 2026.03.12
11	신주발행공고	2025.12.29	1,305
익명 1,305 2025.12.29
10	iLeadBMS Presents Preclinical Data on Novel Drug Candidate for Heart Failure at AFDD	2024.11.21	2,327
익명 2,327 2024.11.21
9	iLeadBMS Presents Preclinical Data on IL21120033 for Heart Failure at ACC 2025	2025.03.31	2,523
익명 2,523 2025.03.31
8	iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis	2025.02.13	2,676
익명 2,676 2025.02.13
7	iLeadBMS Announces Positive Liver Fibrosis Results of IL1512 (CXCR7 Agonist) at the EASL 2024	2024.07.10	2,753
익명 2,753 2024.07.10
6	iLeadBMS Presents Preclinical Data on IL21120033, a First-in-Class ACKR3 Ago-PAM at EULAR 2025	2025.06.14	2,973
익명 2,973 2025.06.14
5	iLeadBMS Announces Positive Preclinical Results of IL1512 (CXCR7 Agonist) at the ATS 2024	2024.05.21	3,065
익명 3,065 2024.05.21
4	Ildong Pharmaceutical Group’s ‘iLeadBMS’ Presents Non-Clinical Results of its Novel NASH Drug Candidate at the AASLD	2022.11.09	3,186
익명 3,186 2022.11.09
3	iLeadBMS’ Cyclin-K Molecular Glue Receives ODD from FDA for Gastric Cancer	2024.10.07	3,557
익명 3,557 2024.10.07
2	iLeadBMS Announces Results of TPD Molecular Glue Research of IL2106 (CDK12 Molecular Glue and Cyclin-K degrader) at ESMO TAT 2024	2024.02.27	3,973
익명 3,973 2024.02.27
1	Ildong Pharmaceutical Invests KRW 13,000,000,000 in iLeadBMS to Strengthen the Ecosystem of Novel Drug R&D	2021.07.15	7,004
익명 7,004 2021.07.15

1페이지

INVESTORS & MEDIA

INVESTORS & MEDIA

NEWS & EVENT